Unknown.png
Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
January 27, 2022 07:30 ET | Excision BioTherapeutics
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE...
Excision Logo.jpg
Excision BioTherapeutics Expands Management Team with Three Key Appointments
October 12, 2021 08:00 ET | Excision BioTherapeutics
Sara Turken, J.D., as General CounselManish Anand, M.Sc., as Senior Vice President, Regulatory AffairsRobert Gunning, CPA, CGMA, as VP, Controller SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- ...
Excision Logo.jpg
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
September 15, 2021 08:00 ET | Excision BioTherapeutics
EBT-101, first-in-human CRISPR-based one-time gene therapy to be evaluated in individuals with HIVInitiation of EBT-101 Phase 1/2 clinical trial expected later this year SAN FRANCISCO, Sept. 15,...
Excision Logo.jpg
Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
August 26, 2021 08:00 ET | Excision BioTherapeutics
CRISPR-based therapies as a curative approach to HIV infection included in the program for first time.Collaboration with Temple University includes research on EBT-101, a CRISPR-based therapeutic...
Excision Logo.jpg
Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer
July 29, 2021 08:00 ET | Excision BioTherapeutics
SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of...
Excision Logo.jpg
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine
May 27, 2021 08:00 ET | Excision BioTherapeutics
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision Logo.jpg
Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing
May 24, 2021 08:00 ET | Excision BioTherapeutics
SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision Logo.jpg
Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board
May 05, 2021 08:00 ET | Excision BioTherapeutics
SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision Logo.jpg
Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer
May 03, 2021 08:00 ET | Excision BioTherapeutics
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision Logo.jpg
Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development
April 01, 2021 08:00 ET | Excision BioTherapeutics
SAN FRANCISCO, April 01, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...